Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $326

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $330 to $326.